Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial

Circulation. 2019 Jan 15;139(3):410-412. doi: 10.1161/CIRCULATIONAHA.118.034993.

Salim S Virani^{1

2

3

4

5}, Julia M Akeroyd¹, Vijay Nambi^{2

3

4

5}, Erin D Michos⁶, Pamela B Morris⁷, Khurram Nasir⁸, Sidney C Smith Jr⁹, Neil J Stone¹⁰, Laura A Petersen¹, Christie M Ballantyne^{2

3

5}

¹ Health Policy, Quality & Informatics Program, Michael E. DeBakey Veterans Affairs Medical Center Health Services Research and Development Center for Innovations, Houston, TX (S.S.V., J.M.A.., L.A.P.).
² Section of Health Services Research (S.S.V., J.M.A.., L.A.P.), Department of Medicine, Baylor College of Medicine, Houston, TX.
³ Section of Cardiovascular Research (S.S.V., V.N., C.M.B.), Department of Medicine, Baylor College of Medicine, Houston, TX.
⁴ Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX (S.S.V., V.N.).
⁵ Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, TX (S.S.V., V.N., C.M.B.).
⁶ Ciccarone Center for Prevention of Heart Disease, Johns Hopkins University, Baltimore, MD (E.D.M.).
⁷ Medical University of South Carolina, Charleston (P.B.M.).
⁸ Center for Healthcare Advancement & Outcomes at Baptist Health South Florida, Miami (K.N.).
⁹ Division of Cardiology, McAllister Heart Institute, University of North Carolina at Chapel Hill (S.C.S.).
¹⁰ Northwestern University Feinberg School of Medicine, Chicago, IL (N.J.S.).

No abstract available

Keywords: cholesterol; clinical trial.

Publication types